SCHEMBL28638009

SCHEMBL28638009

CC(C)(C)OC(=O)N1CCC(c2ccc(NC3CC(=O)NC3=O)cc2)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 8/20 0.64
CRBN Q96SW2 8/20 0.64
NAMPT P43490 1/20 0.57
ALDH1A1 P00352 2/20 0.52
MAPT P10636 2/20 0.51
NPC1 O15118 1/20 0.51
MAPK1 P28482 1/20 0.51
HTT P42858 1/20 0.51
RAB9A P51151 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
GAA P10253 1/20 0.50
TSHR P16473 1/20 0.50
IGF1R P08069 1/20 0.49
KDM4E B2RXH2 1/20 0.48
THRB P10828 1/20 0.48
PTPN2 P17706 1/20 0.48
PTPN1 P18031 1/20 0.48
PTPN6 P29350 1/20 0.48
GPR119 Q8TDV5 2/20 0.45
JAK1 P23458 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22119702 1.00 DDB1 (0.64) DDB1CRBNNAMPTALDH1A1MAPT
SCHEMBL21965763 0.92 DDB1 (0.77) DDB1CRBNNAMPTALDH1A1MAPT
SCHEMBL29946906 0.92 DDB1 (0.77) DDB1CRBNNAMPTALDH1A1MAPT
SCHEMBL23539242 0.92 DDB1 (0.77) DDB1CRBNNAMPTALDH1A1MAPT
SCHEMBL23538462 0.92 DDB1 (0.77) DDB1CRBNNAMPTALDH1A1MAPT
SCHEMBL31323629 0.89 DDB1 (0.73) DDB1CRBNNAMPTALDH1A1MAPT
SCHEMBL22119499 0.88 DDB1 (0.58) DDB1CRBNNAMPTALDH1A1MAPT
SCHEMBL28629401 0.88 DDB1 (0.58) DDB1CRBNNAMPTALDH1A1MAPT
SCHEMBL29946998 0.87 DDB1 (0.73) DDB1CRBNNAMPTALDH1A1MAPT
SCHEMBL25169785 0.86 DDB1 (0.69) DDB1CRBNNAMPTALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015338-A1 TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2026-01-15 US disclosed
US-12454521-B2 Targeted protein degradation C4 THERAPEUTICS, INC. 2025-10-28 US disclosed
US-20220372016-A1 TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2022-11-24 US disclosed
CN-113453679-A Targeted protein degradation C4医药公司 2021-09-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015338-A1 TARGETED PROTEIN DEGRADATION PSMC3, PSMA6, ADRM1 DDB1 716/4885CRBN 17/4885NAMPT 4868/4885
US-20220372016-A1 TARGETED PROTEIN DEGRADATION STUB1, MDM2, UBE3A DDB1 219/4885CRBN 55/4885NAMPT 3483/4885
US-12454521-B2 Targeted protein degradation STUB1, MDM2, UBE3A DDB1 219/4885CRBN 55/4885NAMPT 3483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.